1-12 of 12
Sarat Chandarlapaty
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer

Angela K. Green, Qin Zhou, Alexia Iasonos, William A. Zammarrelli, Britta Weigelt, Lora H. Ellenson, Rashmi Chhetri-Long, Pooja Shah, Jade Loh, Vania Hom, Pier Selenica, Joseph Erinjeri, Iva Petkovska, Sarat Chandarlapaty, Seth Cohen, Rachel Grisham, Jason Konner, Maria M. Rubinstein, William Tew, Tiffany Troso-Sandoval, Carol Aghajanian, Vicky Makker
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-1999
Published: 19 November 2024
View article titled, A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer
Open the PDF for A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A012: Kmt2c/d loss primes urothelium for tumorigenesis and redistributes Menin to bivalent promoters

Naitao Wang, Mohini Pachai, Dan Li, Cindy Lee, Sarah Warda, Makhzuna Khudoynazarova, Woo Hyun Cho, Guojia Xie, Fengshen Kuo, Sagar Shah, Li Yao, Cheng Qian, Elissa Wong, Juan Yan, Fanny Tomas, Wenhuo Hu, Sizhi Gao, Alison Smith, Ming Han, Dong Gao, Kai Ge, Haiyuan Yu, Sarat Chandarlapaty, Gopakumar Iyer, Jonathan Rosenberg, David Solit, Hikmat AI-Ahmadie, Ping Chi, Yu Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10_Supplement): A012.
https://doi.org/10.1158/1557-3265.BLADDER24-A012
Published: 17 May 2024
View article titled, Abstract A012: <em>Kmt2c/d</em> loss primes urothelium for tumorigenesis and redistributes Menin to bivalent promoters
Journal Articles

An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, Jose Alejandro Perez Fidalgo, Rafael Villanueva-Vázquez, Jennifer Giltnane, Mary Gates, Ching-Wei Chang, Sravanthi Cheeti, Jill Fredrickson, Xiaojing Wang, Ann Collier, Heather M. Moore, Ciara Metcalfe, Jennifer Lauchle, Eric W. Humke, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2781–2790.
https://doi.org/10.1158/1078-0432.CCR-23-0011
Published: 01 August 2023
View article titled, An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Open the PDF for An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer

Komal Jhaveri, Joshua Z. Drago, Payal Deepak Shah, Rui Wang, Fresia Pareja, Fanni Ratzon, Alexia Iasonos, Sujata Patil, Neal Rosen, Monica N. Fornier, Nancy T. Sklarin, Sarat Chandarlapaty, Shanu Modi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 3867–3875.
https://doi.org/10.1158/1078-0432.CCR-21-0047
Published: 15 July 2021
View article titled, A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <em>PIK3CA</em>-Mutated HER2-Positive Metastatic Breast Cancer
Open the PDF for A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <em>PIK3CA</em>-Mutated HER2-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors

Sara M. Tolaney, Khanh T. Do, Joseph P. Eder, Patricia M. LoRusso, Colin D. Weekes, Sarat Chandarlapaty, Ching-Wei Chang, Shang-Chiung Chen, Denise Nazzal, Eva Schuth, Flavia Brunstein, Montserrat Carrasco-Triguero, Walter C. Darbonne, Jennifer M. Giltnane, William M. Flanagan, S. Renee Commerford, Alexander Ungewickell, Geoffrey I. Shapiro, Shanu Modi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (21): 5588–5597.
https://doi.org/10.1158/1078-0432.CCR-20-1067
Published: 02 November 2020
View article titled, A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Open the PDF for A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3947–3957.
https://doi.org/10.1158/1078-0432.CCR-19-3953
Published: 03 August 2020
View article titled, Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Open the PDF for Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma

Rita A. Sakr, Britta Weigelt, Sarat Chandarlapaty, Victor P. Andrade, Elena Guerini-Rocco, Dilip Giri, Charlotte K.Y. Ng, Catherine F. Cowell, Neal Rosen, Jorge S. Reis-Filho, Tari A. King
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2326–2337.
https://doi.org/10.1158/1078-0432.CCR-13-2267
Published: 30 April 2014
View article titled, PI3K Pathway Activation in High-Grade Ductal Carcinoma <em>In Situ</em>—Implications for Progression to Invasive Breast Carcinoma
Open the PDF for PI3K Pathway Activation in High-Grade Ductal Carcinoma <em>In Situ</em>—Implications for Progression to Invasive Breast Carcinoma in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: HER3 Targeted Therapy

Kinisha Gala, Sarat Chandarlapaty
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1410–1416.
https://doi.org/10.1158/1078-0432.CCR-13-1549
Published: 13 March 2014
View article titled, Molecular Pathways: HER3 Targeted Therapy
Open the PDF for Molecular Pathways: HER3 Targeted Therapy in another window
Journal Articles

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Sarat Chandarlapaty, Rita A. Sakr, Dilip Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford Hudis, Tari A. King
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (24): 6784–6791.
https://doi.org/10.1158/1078-0432.CCR-12-1785
Published: 16 December 2012
View article titled, Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Open the PDF for Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Shanu Modi, Alison Stopeck, Hannah Linden, David Solit, Sarat Chandarlapaty, Neal Rosen, Gabriella D'Andrea, Maura Dickler, Mary E. Moynahan, Steven Sugarman, Weining Ma, Sujata Patil, Larry Norton, Alison L. Hannah, Clifford Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5132–5139.
https://doi.org/10.1158/1078-0432.CCR-11-0072
Published: 31 July 2011
View article titled, HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Open the PDF for HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab in another window
Includes: Supplementary data
Journal Articles

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

Maurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, Claudia Aura, José Jimenez, Pier Davide Angelini, Gertrudis Sánchez, Marta Guzman, Josep Lluis Parra, Catherine Ellis, Robert Gagnon, Maria Koehler, Henry Gomez, Charles Geyer, David Cameron, Joaquin Arribas, Neal Rosen, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (9): 2688–2695.
https://doi.org/10.1158/1078-0432.CCR-09-3407
Published: 28 April 2010
View article titled, Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
Open the PDF for Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor in another window
Includes: Supplementary data
Journal Articles

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

Sarat Chandarlapaty, Ayana Sawai, Qing Ye, Anisa Scott, Melanie Silinski, Ken Huang, Pat Fadden, Jeff Partdrige, Steven Hall, Paul Steed, Larry Norton, Neal Rosen, David B. Solit
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (1): 240–248.
https://doi.org/10.1158/1078-0432.CCR-07-1667
Published: 02 January 2008
View article titled, SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers
Open the PDF for SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers in another window